Cost-Utility Analysis of Esketamine for Patients with Treatment-Resistant Depression in Italy

AIM: Major depressive disorder is considered one of the most frequent diseases in the general population, and treatment-resistant depression (TRD) represents the subset with more significant clinical and social impact. Large, robust phase III studies have shown safety and efficacy of esketamine nasa...

Descripción completa

Detalles Bibliográficos
Autores principales: Rognoni, Carla, Falivena, Camilla, Costa, Francesco, Armeni, Patrizio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2023
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9883339/
https://www.ncbi.nlm.nih.gov/pubmed/36662417
http://dx.doi.org/10.1007/s40273-022-01220-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9883339/
https://www.ncbi.nlm.nih.gov/pubmed/36662417
http://dx.doi.org/10.1007/s40273-022-01220-z

Ejemplares similares